Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy

BACKGROUND: Poorly immunogenic tumors are hardly responsive to immunotherapies such as immune checkpoint blockade (ICB) and are, therefore, a therapeutic challenge. Combination with other immunotherapies and/or immunogenic therapies, such as radiotherapy (RT), could make these tumors more immune res...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Autores principales: Olivo Pimentel, Veronica, Marcus, Damiënne, van der Wiel, Alexander MA, Lieuwes, Natasja G, Biemans, Rianne, Lieverse, Relinde IY, Neri, Dario, Theys, Jan, Yaromina, Ala, Dubois, Ludwig J, Lambin, Philippe
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7944996/
https://ncbi.nlm.nih.gov/pubmed/33688020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001764
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares